HomeCompareRVLP vs SPHD

RVLP vs SPHD: Dividend Comparison 2026

RVLP yields 7092.20% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVLP wins by $1884093739015635.50M in total portfolio value
10 years
RVLP
RVLP
● Live price
7092.20%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1884093739015635.50M
Annual income
$1,833,245,317,704,596,000,000.00
Full RVLP calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — RVLP vs SPHD

📍 RVLP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVLPSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVLP + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVLP pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVLP
Annual income on $10K today (after 15% tax)
$602,836.88/yr
After 10yr DRIP, annual income (after tax)
$1,558,258,520,048,906,500,000.00/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, RVLP beats the other by $1,558,258,520,048,906,500,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVLP + SPHD for your $10,000?

RVLP: 50%SPHD: 50%
100% SPHD50/50100% RVLP
Portfolio after 10yr
$942046869507817.75M
Annual income
$916,622,658,852,298,000,000.00/yr
Blended yield
97.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RVLP right now

RVLP
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
-11.5
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVLP buys
0
SPHD buys
0
No recent congressional trades found for RVLP or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVLPSPHD
Forward yield7092.20%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1884093739015635.50M$26.5K
Annual income after 10y$1,833,245,317,704,596,000,000.00$567.37
Total dividends collected$1880686879940887.75M$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RVLP vs SPHD ($10,000, DRIP)

YearRVLP PortfolioRVLP Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$719,920$709,219.86$11,130$430.50+$708.8KRVLP
2$48,488,208$47,717,893.43$12,357$447.82+$48.48MRVLP
3$3,055,533,336$3,003,650,953.86$13,687$464.65+$3055.52MRVLP
4$180,164,837,337$176,895,416,667.11$15,126$480.98+$180164.82MRVLP
5$9,940,782,885,418$9,748,006,509,468.02$16,682$496.78+$9940782.87MRVLP
6$513,306,198,719,386$502,669,561,031,988.20$18,362$512.03+$513306198.70MRVLP
7$24,807,223,019,401,092$24,257,985,386,771,350.00$20,174$526.72+$24807223019.38MRVLP
8$1,122,195,624,531,859,500$1,095,651,895,901,100,200.00$22,127$540.84+$1122195624531.84MRVLP
9$47,521,889,075,737,830,000$46,321,139,757,488,740,000.00$24,230$554.39+$47521889075737.80MRVLP
10$1,884,093,739,015,635,500,000$1,833,245,317,704,596,000,000.00$26,493$567.37+$1884093739015635.50MRVLP

RVLP vs SPHD: Complete Analysis 2026

RVLPStock

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Full RVLP Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this RVLP vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVLP vs SCHDRVLP vs JEPIRVLP vs ORVLP vs KORVLP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.